Entera Bio
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Hadassah Bio Park Fl 5, Jerusalem, Jerus...Phone Number
+972 25327151Website
www.enterabio.comRevenue
<$5 MillionStock Symbol
ENTXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Entera Bio
Entera is a leader in the development of orally delivered macromolecules, including peptides and other therapeutic proteins. The Company focuses on significant unmet medical needs where a mini daily tablet form of a peptide treatment or replacement therapy holds the potential to transform the standard of care. The Company’s most advanced product candidates, EB613 for the treatment of high risk, post-menopausal osteoporosis and EB612 for the treatment of hypoparathyroidism, are in clinical development.Explore more
Entera Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Entera Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Entera Bio launches new products
Check out if Entera Bio is spiking on competitors!
Click to see if Entera Bio had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Entera Bio has new funding data
Check if Entera Bio has recently received funding, and reach out quickly before it becomes old news!
Entera Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Entera Bio recently announced quarterly report
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Entera Bio
Recommended Actions
Reach out to Masked Content who joined Entera Bio as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Entera Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Entera Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Entera Bio.
Entera Bio financials insights
Gather financial insights about Entera Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$7.5M
Entera Bio Tech Stack
A closer look at the technologies used by Entera Bio
Most Recent Scoops
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Earnings
Earnings, Finance
Entera Bio News & Media
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to submit a New Drug Application (NDA) for EB613Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
EB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts across its oral peptide pipeline have been accepted for presentation at ENDO 2026, the annual meeting of the Endocrine Society, taking place June 13-16, 2026 in Chicago, Illinois, USA. Notably, new clinical data supporting Entera’s single EB613 tablet as the final candidate for its planned
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Entera Bio
Sign Up For FreeTo access detailed company insights
Entera is a leader in the development of orally delivered macromolecules, including peptides and other therapeutic proteins. The Company focuses on significant unmet medical needs where a mini daily tablet form of a peptide treatment or replacement therapy holds the potential to transform the standard of care. The Company’s most advanced product ca... Read More
